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Abstract: Ovarian cancer is the most lethal gynecological malignancy, often because of the frequent
insurgence of chemoresistance to the drugs currently used. Thus, new therapeutical agents are
needed. We tested the toxicity of 16 new DNA-intercalating agents to cisplatin (cDDP)-sensitive
human ovarian carcinoma cell lines and their resistant counterparts. The compounds were the
complexes of Pt(II) or Pd(II) with bipyridyl (bipy) and phenanthrolyl (phen) and with four different
thiourea ancillary ligands. Within each of the four series of complexes characterized by the same
thiourea ligand, the Pd(phen) drugs invariably showed the highest anti-proliferative efficacy. This
paralleled both a higher intracellular drug accumulation and a more efficient DNA intercalation
than all the other metal-bidentate ligand combinations. The consequent inhibition of topoisomerase
II activity led to the greatest inhibition of DNA metabolism, evidenced by the inhibition of the
expression of the folate cycle enzymes and a marked perturbation of cell-cycle distribution in both
cell lines. These findings indicate that the particular interaction of Pd(II) with phenanthroline confers
the best pharmacokinetic and pharmacodynamic properties that make this class of DNA intercalators
remarkable inhibitors, even of the resistant cell growth.
Keywords: cisplatin-resistance; DNA intercalators; ovarian cancer cells; topoisomerase II; thymidylate
synthase; bipyridine; phenanthroline; Pt(II); Pd(II); thioureas
1. Introduction
The importance of intercalating drugs in the treatment of solid tumours, including ovarian cancer,
has been highlighted by a recent guidance from the National Institute for Health and Care Excellence
(NICE) that recommends pegylated liposomal doxorubicin hydrochloride (PLDH), alone or alongside
platinum, for treating recurrent ovarian cancer [1].
Many of the clinically used DNA-intercalating agents are potent inhibitors of both DNA and
RNA synthesis [2,3], and this is considered their primary mode of action. In addition, DNA damage,
for example, through micronuclei formation, can result from interference of most DNA-intercalating
agents with topoisomerase II (TOPO-II), an enzymatic protein with the role of maintaining the correct
topological properties of DNA in cells [3].
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As a development of studies on non-covalent interactions of square-planar Pt(II) complexes
intercalating the DNA duplex [4], bipyridyl (bipy) complexes of Pt(II) with thiourea were reported as a
new class of efficient DNA intercalators that exploit (i) the bipy moiety to insert between base pairs, (ii)
the Pt(II) core size and coordination to impose molecular geometry and provide the positive charge,
and (iii) the strong binding of the thiourea ligands to Pt(II) to avoid unwanted covalent reactions with
nucleobases [5].
The biological activities of some bipy complexes of Pt(II) with various substituted thioureas,
designed to intercalate into DNA, were tested against cisplatin (cDDP)-sensitive and –resistant human
ovarian carcinoma cell lines [6]. cDDP is an anticancer drug in clinical use for the treatment of
malignancies of the urogenital tract and other solid cancers [7]. However, its clinical success is
often diminished by intrinsic and acquired tumour resistance. This is a multifactorial process that
also includes specific cellular modifications that have been shown to be responsible for resistance
to DNA-intercalating agents or to be present in cell lines, which display cross-resistance to both
classes of drugs. In this regard, cross-resistance to the DNA intercalator doxorubicin was observed in
cDDP-resistant cancer cell lines with high levels of glutathione, and/or an increased DNA TOPO-II
activity and with a P-gp-mediated multi-drug resistance phenotype [8].
We have shown that the anti-proliferative efficacy of tested Pt(II)-bipyridyl-substituted thiourea
complexes increases with the ancillary thiourea-ligand bulkiness and the hydrophobicity of its
substituents. In particular, the presence of two phenyl groups on the thiourea moiety confers them an
outstanding cytotoxicity, even against cDDP-resistant cells. Cell growth inhibition partially paralleled
drug accumulation. Instead, drug intercalation into DNA was favoured by the planarity of the bipyridyl
mojety [9].
Subsequently, the chemical variety of these complexes was significantly widened by the synthesis
and structural characterization of several Pd(II) bipy and 1,10-phenanthroline (phen) complexes
with N-alkyl substituted thioureas as the ancillary ligands [10] and Pt(II) [11]. The capability of
1,10-phenantroline to interact with nucleic acid base pairs has been clearly explained [12]. Both AT and,
more strongly, GC base pairs bind phenanthroline. The predicted stacked structure of the complex of
phen with AT base pairs is found complementary to the available crystal structure. However, in certain
crystal structures, the phen ligand is found partially intercalated within two thymine nucleobases [13].
Recently, Barra et al. [14] have addressed the structural determinants of the bioactivity of Pd(II)
complexes of general formulae [Pd(phen)(tu)2]2+, incorporating the intercalator phen and thiourea
(tu) with the latter either unsubstituted or N-methyl- or N,N-dimethyl-substituted. DNA binding
experiments suggested that the ancillary thiourea ligands did not affect the intercalating ability,
as already observed for Pt-bipy-thiourea complexes [6]. These observations indicate that the DNA
binding affinity of these compounds is only a partial determinant of the observed cytotoxicity differences.
Indeed, pharmacological targets other than TOPO-II cannot be excluded. In this light, a study on
complexes of the type [Pt(N–N)(L–L)]2+ (N–N = phen derivatives, L–L = bidentate ancillary ligand)
highlighted the influence of the ancillary ligand, particularly in terms of interactions with non-DNA
receptors [15].
In the present work, we tested the relevance of the nature of the metal ions, Pt(II) and Pd(II),
as well as of the bidentate (bipy and phen) and ancillary ligands, on the cytotoxicity of metal-bidentate
ligand-thiourea complexes in ovarian cancer cells, also shedding light on such mechanistic determinants
as cellular internalization of the complexes and their ability to intercalate DNA and to inhibit TOPO-II.
We evaluated and compared biological and some correlated biochemical activities of four series of
compounds, each characterized by a different thiourea ligand, namely, unsubstituted, methyl-, n-butyl-,
and di-ethyl-substituted thiourea. Each series included the four complexes of Pt(II) and Pd(II) with
bipy and phen and the thiourea (see Figure 1). The sixteen combined complexes were characterized for
their ability to intercalate DNA and tested in cDDP-sensitive human ovarian cancer cell lines and in
their resistant counterparts, whose resistant phenotype was accompanied by some of the intracellular
modifications conferring resistance to DNA-intercalating agents.
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Figure 1. General chemical structure of Pt(II) and Pd(II) (M) complexes with 1,10-phenanthroline or 
2,2′-bipyridine (represented as the bidentate ligand, N͜͜‿N) and thioureas. A: X = X′ = H; B: X = H, X′ = 
CH3; C: X = H; X′ = n-Bu; D: X = X′ = C2H5. The series A, B, C, and D include the complexes with the 
indicated substituents on thioureas. 
2. Results 
2.1. Comparison of the Cytotoxic Efficacy of the Different Complexes 
To highlight the role of the substituents on the thiourea moiety, the Pt(phen) and Pd(bipy) 
complexes were divided into four series: series A, no substituents; series B, methyl; series C, n-buthyl; 
and series D, bis-ethyl (Figure 1). 
Cytotoxic activity of the complexes of the four series was studied against two pairs of human 
ovarian carcinoma cell lines, the cDDP-sensivitive 2008 and A2780, and their resistant counterparts, 
C13* and A2780/CP (Figure 2 and Table S1). As shown in Figure 2, the order of increasing potency 
on all the cell lines was Pt(bipy) < Pt(phen) < Pd(bipy) < Pd(phen). In particular, the Pt(bipy) 
complexes were the least toxic, with IC50 values ranging from about 120 to 240 µM on sensitive cell 
lines, and from 150 to 445 µM on resistant cell lines (Table S1). On the other hand, the Pd(phen) 
complexes were the most active ones against all cancer cell lines, displaying low µM IC50 values 
(Table S1). The Pt(phen) and Pd(bipy) complexes showed similar dose-response curves as well as IC50 
values. 
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CH3; C: X = H; X′ = n-Bu; D: X = X′ = C2H5. The Series A, B, C, and D include the complexes with the
indicated substituents on thioureas.
2. Results
2.1. Comparison of the Cytotoxic Efficacy of the Different Complex
To highlight the role of the substituents on the thiourea moiety, the Pt(phen) and Pd(bipy)
complexes were divided into four s ies: Series A, no s bstituents; Series B, methyl; S ries C, n-buthyl;
and Series D, bis-ethyl (Figure 1).
Cytotoxic activity of the complexes of the four series was studied against two pairs of human
ovarian carcinoma cell lines, the cDDP-s nsivitive 2008 and A2780, and their resistant counterparts,
C13* a d A2780/CP (Figure 2 and Table S1). As shown n Figure 2, the order of increasing potency on
all the cell lines as Pt(bipy) < Pt(phen) < Pd(bipy) < Pd(phen). In particular, the Pt(bipy) complexes
were the least toxic, with IC50 values ranging from about 120 to 240 µM on sensitive cell lines, and from
150 to 445 µM on resistant cell lines (Table S1). On the other hand, the Pd(phen) complexes were the
most active ones against all cancer cell lines, displaying low µM IC50 values (Table S1). The Pt(phen)
and Pd(bipy) complexes showed similar dose-response curves as well as IC50 values.
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Figure 2. Dose-dependent effects of Pt- and Pd-thiourea complexes of the A and B series (left panels)
and of the C and D series (right panels) on the growth of 2008 and C13* cells after a 2 day exposure.
Results represent the mean of three separate experiments performed in duplicate. Error bars, standard
error of the mean (SEM).
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Interestingly, among the Pt(II)-thiourea complexes with either bipy or phen, the cytotoxicity
was increased by the presence of binding ancillary ligands with respect to unsubstituted thiourea
complexes, confirming a previous report [6]. This effect occurred to a lesser extent with Pd(II)-thiourea
complexes. Nevertheless, the Pd(phen) drugs showed the highest effectiveness whether or not they
bore ligands on the respective thioureas.
Their cytotoxic potency was also compared to both cDDP and doxorubin (Table S2), resulting
in actually being lower than doxorubicin; however, in the resistant cells they were more or equally
effective to cisplatin. As a result, the related resistant factor (RF) values were better than those obtained
with both chemotherapy drugs, even with doxorubicin, indicating that the Pd(phen) complexes were
able to kill cancer cells even in the presence of the resistance phenotype.
2.2. Remarkable Intracellular Accumulation of the Pd(phen) Complexes
Looking for a correlation between the cytotoxicity and the cellular uptake of the complexes,
we determined the 195Pt and 105Pd intracellular concentrations from total cell homogenates using
inductively-coupled plasma mass spectrometry (ICP-MS), a technique characterized by very low
detection limits for most elements, 1 to 10 ppt for Pd and <0.1 to 1 ppt for Pt.
To better compare the accumulations of very active complexes with those of the scantily cytotoxic
forms, 2008 and C13* cells were exposed for 24 h to the same drug concentration (5 µM), close to the
IC50 values of most Pd(phen) complexes. The Pd(phen)-thioureas actually accumulated from three
to sevenfold more than the other complexes in both cell lines (Figure 3), almost reaching 800 pmol
Pd/mg of protein, whereas Pt(bipy), Pd(bipy), and Pt(phen) complexes never reached 300 pmol Pt/mg
or Pd/mg of protein. The Pd(phen) accumulation was always statistically larger than that of the other
complexes with p < 0.001.
In trying to explain the differences in cellular accumulation as to why Pd(phen) accumulated at
much higher levels, we evaluated the lipophilicity of our complexes. Although unable to distinguish
between Pt or Pd complexes, the Chembiodraw ultra 12.0 software [16] gave us a useful hint to
partially account for the greater accumulation of the Pd(phen) compounds, as it indicated a higher
lipophylicity of phenanthroline complexes with respect to bipyridyl complexes, with logP values of
2.89 and 2.42, respectively.
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2.3. Pd(phen) Complexes Showed the Highest Affinity for DNA and Intercalation Ability
In the next step of our effort to rationalize the cytotoxicity results, we tested the ability of
these complexes to bind DNA by intercalating between bases [10,11,14,17]. We thus compared the
intercalation ability of the eight complexes of the Series A and C by means of an ethidium bromide (EB)
fluorometric displacement assay that took advantage of the much higher fluorescence quantum yield
of DNA-bound EB relative to free EB [6,18]. The assay consisted in measuring the emission spectrum
of EB in the presence of DNA while another DNA ligand able to displace EB was progressively added.
To determine the DNA-binding affinity of the incoming ligand from analysis of the EB emission
intensity values (see the Experimental Section 4.5 for the details), we need to know the DNA-binding
properties, affinity, and stoichiometry, of the displaced ligand, EB in our case. From a Scatchard-type
analysis (Figure S1), we determined the EB binding equilibrium constant and stoichiometry for the
employed calf thymus DNA to be 1 × 106 M−1 and 1 EB molecule per 2.5 base pairs, in keeping with
reported values [19]. From the subsequent fluorometric titrations for the displacement of EB from
DNA by a Pd or Pt complex (Figure 4), we determined the dissociation equilibrium constants, Kd, and
the corresponding ∆G◦ for the binding to DNA of the eight complexes investigated. These values are
reported in Table 1 in order of decreasing binding affinity. It is quite apparent that phenanthroline
Int. J. Mol. Sci. 2019, 20, 6122 6 of 18
complexes intercalated better than bipyridyl complexes. As for the metal, the Pd-phen combination
performed only slightly better than the Pt-phen combination, whereas when bipy was the bidentate
ligand no conclusion about the effect of a change in the metal could be drawn. The nature of the
ancillary ligand seemed to affect affinity to some extent, though not in a consistent way in the complexes
investigated. The introduction of the bulky n-butyl substituents on the thiourea ligands increased
the affinity for DNA in three out of four tested complex pairs, namely Pt(phen) (∆G◦ = 1.7 kJ mol−1),
Pt(bipy) (∆G◦ = 4.3 kJ mol−1), and Pd(bipy) (∆G◦ = 1.7 kJ mol−1). On the other hand, a small affinity
decrease (∆G◦ = −1 kJ mol−1) was found with the Pd(phen) pair.
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Figure 4. Fluorometric titrations for the displacement of ethidium bromide from calf-thymus DNA
with Pt(II) and Pd(II) phen or bipy thiourea complexes. The estimated uncertainty of each data point
was ± 10%. tu = thiourea; nBut = n-butyl. T = 22 ± 2 ◦C. Each curve represents the dependence of
the normalized fluorescence intensity re-calculated as described in Section 4.5 of the Materials and
Methods using the best dissociation equilibrium constant (Kd) for each displacing metal complex.
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Table 1. Dissociation equilibrium constants and corresponding ∆G◦ for the binding of the given metal
complexes to calf thymus DNA.
Complex Kd/10−8 M ∆G◦/kJ mol−1
[Pd(phen)tu2]Cl2 6 40.8
[Pd(phen)(nBut-tu)2]Cl2 9 39.8
[Pt(phen)(nBut-tu)2]Cl2 20 37.8
[Pt(phen)tu2]Cl2 40 36.1
[Pt(bipy)(nBut-tu)2]Cl2 50 35.6
[Pd(bipy)(nBut-tu)2]Cl2 100 33.9
[Pd(bipy)tu2]Cl2 200 32.2
[Pt(bipy)tu2]Cl2 280 31.3
The uncertainty on the equilibrium constants (Kd) values is estimated to ± 30%. tu = thiourea, nBut = n-butyl.
T = 22 ± 2 ◦C.
2.4. Pd(phen) Complexes Caused the Greatest Perturbation of Cell Cycle and Apoptosis Induction
To assess whether a perturbation of the distribution of cells in the different phases of the cell cycle
was a possible mechanism underlying the antiproliferative activity of these intercalating agents, the four
Pd(bipy) and the four Pd(phen) complexes were tested in cell-cycle perturbation experiments on the
2008 and C13* cell lines, after 48 h of incubation at concentrations fixed approximately at the IC50 value
of the most active Pd(phen) complexes. The percentage of cells in the different phases of the cell cycle is
reported in Table 2. Untreated cells showed a normal diploid distribution presenting fast proliferation
characteristics. Treatment with all eight compounds produced significant cell-cycle perturbation
with higher accumulation of cells in the G0/G1 phase. The effect was dose-dependent, but to better
compare the effect within each group of complexes, we show here the results obtained at 5 µM for
all drugs. At this concentration, Pd(bipy) complexes caused only a slight perturbation of cell-cycle
phase distribution and no apoptosis. However, at their IC50 concentration (approximately 50 µM), the
effect was comparable with that of Pd(phen) drugs (data not shown). In our experimental conditions,
5 µM Pd(phen) greatly deranged the cell-cycle phase distribution of 2008 cells and, to an even greater
extent, of the C13* cells. The marked accumulation in the G0/G1 cell-cycle phase was coupled to a
decrease in the S and G2/M phases. Moreover, as a result of treatment with all Pd(phen) complexes,
a significant increase of cell population in the sub-G1 phase was observed, which was indicative of
apoptotic cell death (Table 2; Figure S2). In the resistant C13* cells, this effect was slightly reduced by
the resistant phenotype. However, perturbation of cell-cycle and a great percentage of hypodiploid
cells were still visible, in particular, after [Pd(phen)(nBu-tu)2]Cl2 and [Pd(phen)(Et2-tu)2]Cl2 treatment
(Table 2; Figure S3).
Table 2. The distribution (%) of 2008 and C13* cells in the different phases of cell cycle after treatment
with the Pd-bipy-thiourea and Pd-phen-thiourea complexes.
Drugs (5 µM) 2008 Cells C13* Cells
G0/G1 S G2/M Apoptosis G0/G1 S G2/M Apoptosis
Control 66.9 ± 3 11.5 ± 1 14.6 ± 3.5 1.53 ± 1 62.7 ± 4 17.1 ± 2 13.6 ± 2 1.4 ± 0.2
[Pd(bipy)(tu)2]Cl2 69.7 ± 3 12.1 ± 1 14.1 ± 0.2 1.24 ± 0.5 59.7 ± 4 19.8 ± 1 13.7 ± 1 2.1 ± 0.3
[Pd(bipy)(Me-tu)2]Cl2 63.5 ± 5 20.5 ± 3 11.8 ± 1 1.44 ± 0.4 54.2 ± 2 22.7 ± 4 16.8 ± 2 3.4 ± 1.5
[Pd(bipy)(nBu-tu)2]Cl2 73.5 ± 6 12.6 ± 3 12.8 ± 4 1.12 ± 0.2 67.8 ± 5 13.9 ± 2 15.3 ± 3 1.32 ± 0.4
[Pd(bipy)(Et2-tu)2]Cl2 69.6 ± 5 12.7 ± 2 14.2 ± 3 1.30 ± 0.3 66.4 ± 7 14.9 ± 2 14.4 ± 3 1.37 ± 0.4
[Pd(phen)tu2]Cl2 77.2 ± 2 3.2 ± 0.8 4.1 ± 0.2 9.8 ± 1.7 81.6 ± 2 2.3 ± 0.3 3.1 ± 0.3 10.6 ± 0.5
[Pd(phen)(Me-tu)2]Cl2 71.8 ± 1 3.6 ± 1.4 4.6 ± 1.8 14.8 ± 0.7 81.1 ± 2 2.4 ± 0.5 3.4 ± 1.2 9.5 ± 2
[Pd(phen)(nBu-tu)2]Cl2 64.7 ± 2 2.2 ± 0.1 7.2 ± 2.2 24.5 ± 1.1 71.1 ± 6 12.7 ± 2 5.1 ± 2 11.6 ± 2
[Pd(phen)(Et2-tu)2]Cl2 73.3 ± 3 2.4 ± 0.9 5.6 ± 0.8 16.8 ± 0.6 78.6 ± 4 4.5 ± 0.6 3.6 ± 0.4 12.7 ± 3
24 h after seeding, the cells were exposed to 5 µM of each drug for 48 h, then DNA content of untreated and treated
cells was determined by flow cytometry after propidium iodide staining. All results shown are representative of
two/three independent assays.
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2.5. Pd(phen) Complexes Targeted TOPO-II and Thymidylate Synthase (TS) Activity Affecting DNA Integrity
It is well known that intercalating agents, such as doxorubicin, can enter the nucleus and poison
TOPO-II, also resulting in DNA damage and apoptotic cell death [20]. Because of this, we checked
whether our DNA-intercalating metal complexes might differently affect the activity of this enzyme,
thus accounting for the observed differential cytotoxicity.
Figure 5 shows that most of the compounds were actually able to inhibit TOPO-II activity at the
three tested concentrations. However, only phenantroline complexes, probably also correlating with
the higher DNA binding affinity observed, reduced enzyme activity by at least 30% and 50% with
Pt(phen) and Pd(phen) complexes, respectively, even at the lowest concentration (5 µM). A total of 80%
inhibition was obtained with [Pd(phen)(Et2-tu)2]Cl2.
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Figure 5. Inhibition of TOPO-II enzymatic activity. Inhibition of TOPO-II-dependent decatenation of
kDNA following increasing concentrations of complexes versus dimethyl sulfoxide (DMSO) (arbitrarily
set at 100%). (A) Effect of the indicated Pd(bipy) and Pd(phe ) complexes of the A an B or (B) C and
D series. The results represent the mean of three experiments conducted n duplicate. Error bars, SEM.
* p < 0.05; ** p < 0. 1; *** p < 0.001 versus control.
Folate-cycle enzymes, thymidylate synthase (TS), and dihydrofolate reductase (DHFR) in particular
can be included among the enzymes of DNA repair/substitution and cell cycle control, being essential
for nuc eotide synthesis. We t us hypo he ized that a modulation of the expression of these enzymes
by he he e described DNA-intercalating metal complexes might contribute t the obs rved ytotoxicity.
As shown in Figure 6, [Pd(phen) u2]Cl2 actually reduced the TS and DHFR protein l v ls in 2008
cells by about 70% and 40%, respectively. Similarly, [Pd(phen)(Me-tu)2]Cl2 lowered the two pr tein
lev ls by 60% and 35%. In t ese cells, [Pt(phen)(nBu-tu)2]Cl2 was also active in reducing the amount
of both proteins by approximately 40%. The expression of TS was even more greatly affected by
[Pd(phen)(nBu-tu)2]Cl2 and [Pd(phen)(Et2-tu)2]Cl2.
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Figure 6. Effects of Pd(Pt)-bidentate ligand-thiourea complexes on thymidylate synthase (TS) and
dihydrofolate reductase ( FR) expression in 2008 and C13* cells. Western immunoblot analysis
of S a d FR in cells treated for 24 h with the respective IC50 concentrations of the indicated
complex s. human TS (hTS) , lecular ma s of 35 KDa, and DHFR m nomer, molecular
mass of 21 KDa. Representative blot t endent experiments are shown. Human β-actin
was used as internal control for protei l . umbers below the blots correspond to relative TS
and DHFR quantification by densito t r ith control (CTRL), arbit arily se at 100.
An inter sting reduction of TS lev l erved with [Pt(phen)tu2]Cl2, and even more
pron unced against DHFR. On the other hand, [Pd( i )(t )2]Cl2, [Pd(bipy)(Me-tu)2]Cl2, and
[Pd(bipy)(nBu-tu)2]Cl2, at their I 50 values slightly reduced TS level, but diminished DHFR protein
level by over 60%. On the contrary, cisplatin was ineffective on the amount of DHFR but, as expected,
reduced TS expression by about 20% [21,22]. In general, all (Phen)thioureas greatly inhibited the
expression of TS and DHFR and, even if with some differences among the complexes, the reduction
always exceeded 60% with respect to the control untreated samples.
Together with the TS protein levels, the cellular TS activity was reduced by most of the tested
complexes, particularly with 2008 cells. Again, Pd(phen) complexes showed the highest activity
both on 2008 and C13* cells (Figure 7A). To the inhibition of TS protein expression, cells responded
by increasing the uptake of folic acid (FA), probably as a result of a compensation mechanism, but
unexpectedly this enhancement only followed treatment with Pd(phen)thioureas and not with the
Pd(bipy) analogs, despite their effectiveness towards TS activity (Figure 7B).
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3. Discussion
In this work, we analysed the effects of four series of bipyridyl (bipy) and phenanthrolyl (phen)
complexes of Pt(II) or Pd(II) with thioureas in the same cell models previously exploited for evaluating
the biological effects of six Pt(II)-bipy-thiourea complexes [6], four of which, namely, Pt(bipy)-A, -B,
-C, and –D thiourea, were also included in the present study. Our goal here was to explore a broader
variety of metal-bidentate ligand-thiourea complexes. We thus combined two metal ions with the
sa e charge (2+) but different sizes, P (II) a d Pt(II), with two bidentate ligan s, bipy a phen,
and four thioureas t see which ones among these 16 squar planar met l co plexes, reviously
synthetized and chemically characterized [10,11], featured the best biological and chemic l action
against proliferation of human ovar a carcinoma cell lines (2008, C13*).
The biological t r tained revealed that Pd(phen)-thioureas were the most cytotoxic
complexes, with IC50 values lo er by more than two orders of magnitude than the other complexes
with the same thioureas, particularly with respect to Pt(bipy)-thiourea complexes. This difference in
activity could partly result from a larger intracellular accumulation Pd(phen) complexes, suggesting
that, regardless of the substituents on the thiourea moiety, combining Pd with the more lipophilic
bidentate ligand, 1,10-phenanthroline, can allow a more efficient passive transport through the cell
membrane [23] and/or a reduced efflux rate from cells. It is noteworthy in the fact that the Pd(phen)
complexes of each series accumulated best also in the cDDP-resistant C13* cells, though in slightly
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smaller amounts than in the sensitive cells, suggesting a limited involvement of the resistance phenotype
in their accumulation [24,25].
In addition to their greatest intracellular accumulation, Pd(phen) complexes confirmed their
ability to intercalate DNA [26–28] and showed the highest affinities for the calf-thymus DNA base
pairs among the tested complexes, including the corresponding bipy complexes. It has been reported
that both AT and GC base pairs may stably bind the phenanthroline ligand, but its affinity is larger for
the GC base pair [29]. In this regard, some Pd(phen) compounds, including our [Pd(phen)tu2]Cl2 and
[Pd(phen)(Me-tu)2]Cl2, have been suggested to form hydrogen bonds with guanosine [14]. Therefore,
our complexes bearing the phenanthroline moiety, in particular those with Pd(II), are likely powerful
nucleic acid inhibitors. In particular, like the most clinically used DNA intercalating compounds [30],
they may more strongly stabilize, lengthen, stiffen, and unwind the DNA double helix, thus concurring
to the observed remarkable biological effect.
The physiological consequences of the direct alteration of DNA properties may add to the DNA
damage originated from the interference of the metal complex with the activity of TOPO-II [31].
In this regard, we have previously shown that bipyridyl complexes of Pt(II) with thiourea are able
to inhibit TOPO-II activity [9] and, more recently, Barra et al. showed that three Pd(phen) complexes,
including our [Pd(phen)tu2]Cl2 and [Pd(phen)(Me-tu)2]Cl2, were also active as TOPO-II inhibitors in a
dose-dependent manner [14]. We confirmed here that metal phenanthroline complexes were active
TOPO-II inhibitors, and showed again that Pd(phen) were the most active TOPO-II inhibitors among
the tested metal planar complexes, even at the smallest concentration tested. Although a mechanism
of action cannot be exactly proposed [8,32], their interaction with DNA and TOPO-II may result in cell
death via apoptosis [33].
A number of anticancer drugs acting merely via intercalation or alkylation of DNA, such as
doxorubicin and cisplatin, cause DNA damage and perturbation of cell-cycle phase distribution,
subsequently inducing apoptosis in cancerous cells [8,34].
In this work, the tested Pd(phen) thioureas were actually shown to cause a significant increase
of cell population in the sub-G1 phase of 2008 and C13* cell lines, which was indicative of apoptotic
cell death, and the greater arrest in the G0/G1 phase could be associated with TOPO-II inhibition and
potential disturbances of replication or DNA damage. Arrest of cells in the G1 phase is thought to be
an important cellular defence mechanism to prevent replication of damaged DNA [35].
Along with intercalation into DNA base pairs and binding to DNA-associated enzymes including
TOPO-II [20], drugs such as doxorubicin are known to undergo other biological actions, ultimately
contributing to DNA damage, with altered gene expression [34]. Candidate pharmacogenes for this
action include the enzymes involved in the DNA repair mechanisms and the cell cycle control such
as TOP2A, MLH1, MSH2, TP53, and ERCC2 genes [36]. Two enzymes of the folate cycle, TS and
DHFR, are also essential proteins for a normal cell cycle occurrence and DNA synthesis and ensure
the correct substitution of damaged DNA after injury by chemotherapeutics [37]. In this work, the
down-regulation of the TS protein expression by some complexes, especially Pd(phen), might reflect a
characteristic similar to those observed with other DNA damaging agents [38]. The inhibitory effect of
the complexes on TS can also result in imbalances of DNA precursors, such as dTMP, dTDP, and dTTP
pools and others. In fact, the depletion of dTMP and subsequently dTTP induced perturbations in the
levels of the other deoxynucleotides (dATP, dGTP, and dCTP), resulting in a reduction of the DNA
synthesis and repair [39]. These effects suggest that a combinatorial strategy with our complexes and
traditional TS inhibitors, such as 5-fluorouracil, raltitrexed or pemetrexed might have great potential in
killing cells even with innated or more elevated TS levels that are more elevated [40].
Notably, the results shown here suggest that the cisplatin-resistance phenotype can only partly
modulate these effects, as the complexes, Pd(phen) in particular, were almost equally effective against
both sensitive and resistant cells, despite the over-expression, often observed in cDDP-resistant cells,
of some of the enzymes involved in the pharmacology of these complexes, such as TOPO-II [41,42], TS,
and DHFR [43], as well as the multidrug-resistant proteins [24,25].
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In conclusion, we showed that among the 16 complexes obtained by combining the Pd(II) and
Pt(II) metal ions, the bipy and phen bidentate ligands, and four differently substituted thioureas, that
the Pd(phen)-thioureas are by far the most effective tumour-cell growth inhibitors. Their excellent
cytotoxicities (low micromolar IC50s) likely stem from their remarkable intracellular accumulation,
affinity for DNA-base pairs, and ability to modulate the expression of some key enzymes for DNA
metabolism and cellular vitality, all properties in which they proved better than the other metal-bidentate
ligand complexes tested (Pd(bipy), Pt(phen), and Pt(bipy), even in resistant cells.
Finally, the results also suggest that these active complexes may have potential for development
as therapy for ovarian carcinoma based on drug combinations.
Nevertheless, additional pharmacological targets cannot be excluded, and more studies are
necessary to deeply elucidate their mechanism of action.
4. Materials and Methods
4.1. Drugs and Chemicals
The synthesis of the bipy and phen complexes of Pt(II) or Pd(II) with the four thioureas and their
chemical characterization by elemental analysis and 1H- and 13C[1H]-NMR spectroscopy have been
reported previously [10,11]. All other chemicals were purchased from Sigma Chemical Co. (St. Louis,
MO, USA), except where otherwise indicated.
4.2. Cell Lines
The human ovarian carcinoma cell lines 2008, A2780, and their respective resistant counterparts
C13* and A2780/CP were used [44–46]. Cells were grown as monolayers in RPMI 1640 medium
containing 10% heat-inactivated fetal bovine serum and 50 µg/mL gentamycin sulfate. All cell media
and the serum were purchased from Lonza (Verviers, Belgium). Cultures were equilibrated with
humidified 5% CO2 in air at 37 ◦C. All studies were performed in Mycoplasma negative cells, as routinely
determined with the MycoAlert Mycoplasma detection kit (Lonza, Walkersville, MD, USA).
4.3. Cell Growth Assay
The inhibition of proliferation was measured by crystal violet staining, as previously reported [47],
and the concentration at which cellular growth is inhibited by 50% (IC50) was determined following
48 h treatment with compounds. Briefly, the cell monolayer was fixed with methanol and stained
with 0.05% crystal violet solution in 20% methanol for 1 h. The incorporated dye was solubilized in
acidic isopropanol and determined spectrophotometrically with a multiplate reader (TecanGenios Pro
with Magellan 6 software, San Diego, CA, USA) at 540 nm. The extracted dye was proportional to the
cell number.
4.4. Intracellular Complex Accumulation
Intracellular metal concentrations in parts per billion were determined by inductively coupled
plasma mass spectrometry (ICP-MS) [48,49] using a Plasma Spectrometer ICP-MS X SeriesII (Thermo
Fisher Scientific, Waltham, MA, USA) equipped with a CETAC ASX-520 autosampler (Neuss, Germany),
an ablasion laser system NEW WAVE UP 213, a Scott double pass spray chamber, and a MicroMist
nebulizer, at a sample uptake rate of approximately 0.25 mL min−1.
After treatment, the drug-containing medium was completely removed. Wells were washed thrice
with PBS in order to make sure that each drug-exposed well was cleaned appropriately. Cell lysis
was accomplished by addition of 0.5 mL of HCl 0.1 N and Triton X-100 0.1% for 1 h on the rocker.
Subsequently, an aliquot of 400 µL was added to the same volume of sub-boiled HNO3 69% and left at
RT overnight to allow complete mineralization. On the next day, each sample was transferred into a
15 mL polypropylene tube and filled to a total volume of 8 mL with Milli-Q water. Finally, 8 mL of a
Pt(II) or Pd(II) solution (final concentration 0.5 ppb) was added as the internal standard for the ICP-MS
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analysis, performed on the same day. The total amount of the respective metal per well was calculated
and averaged over the three replicates. The Pt(II) and Pd(II) counts were normalized to the amount of
cellular protein (nmol Pt or Pd/mg of protein).
4.5. Measurement of DNA-Intercalating Ability
The ability of each complex to intercalate DNA was determined by the ethidium bromide (EB)
displacement fluorometric assay. Absorption measurements were performed on a double-beam
Varian Cary100 UV-visible spectrophotometer with a cuvette containing the buffer on the reference
beam. Fluorescence emission spectra were measured using a Horiba FluoroMax3 spectrofluorometer.
The excitation wavelength was 525 nm and the emission spectra were measured between 540 and
720 nm. At such wavelengths, no interference on the EB excitation and emission came from the
tested complexes. Also, 4 × 10 mm2 quartz cuvettes were always employed. For the experiment
aimed at characterizing the binding affinity of EB to our calf thymus DNA, 100 µL of 20 µg/mL calf
thymus DNA were added to 900 µL of HEN buffer and the emission spectrum was then measured at
increasing concentrations of EB, determined spectrophotometrically using a molar extinction coefficient
of 5680 M−1 cm−1 at 478 nm [50]. For the displacement experiments, 100 µL of a 20 µg/mL calf
thymus DNA solution was added to 900 µL of HEN buffer and 20 µL of a 2.4 mM EB solution. The
emission spectrum of EB was then measured at increasing concentrations of each added displacing
compound until a stable emission spectrum, due to fully displaced EB, was obtained at 600 nm
(I600). I600 was expressed as the sum of the contributions from free and DNA-bound EB. We first
determined the instrumental proportionality constants between the concentration of each such form
and the corresponding I600. Then, from the spectrophotometrically determined total DNA and EB
concentrations, at each such concentration we calculated the fraction of bound base pairs with a 2.5:1
EB/base pair stoichiometry at saturation to obtain the EB/base pair association constant and the binding
stoichiometry from Scatchard plot linear fitting, to determine the dissociation constants (Kd) for the
Pd and Pt complexes with the DNA, as previously developed [51,52]. In short, for each added metal
complex, the measured I600 values were compared with the values calculated in terms of the previously
determined EB/DNA binding constant and stoichiometry, an assumed Kd for the binding of DNA
with the incoming metal complex, the stoichiometry being kept the same as found with EB, and the
concentrations of EB, DNA base pairs, and metal complex. The best-fitting Kd value was kept. All
experiments were performed at T = 22 ± 2 ◦C.
4.6. TOPO-II Decatenation Assay
TOPO-II activity was assayed in vitro through the Topoisomerase II assay kit (no. TG1001,
TopoGEN Inc., Port Orange, FL, USA), following the instructions of the manufacturer. Nuclear extracts
containing TOPO-II activity were obtained from cells and the ability to decatenate kDNA was analysed
in the presence of DMSO and of the tested complexes, as previously shown [53]. Briefly, decatenation
assay was performed with 50 ng kDNA in a 10 mL reaction mixture containing 50 mM Tris–HCl (pH
8.0); 150 mM NaCl; 10 mM MgCl2; 0.5 mM dithiothreitol; 2 mM ATP; 30 mg/mL BSA with DMSO;
or 5, 15, 30 µM of compounds and 0.5 mg of cell nuclear extract. Reactions were incubated at 37 ◦C
for 30 min and stopped by adding 5 mL of stop buffer (5% Sarkosyl 0.125% bromophenol blue and
25% glycerol). Samples were loaded directly onto a 1% agarose gel containing ethidium bromide
(0.5 mg/mL). TOPO-II activity was measured by the appearance of decatenated minicircular products
and determined as the percentage of DMSO by ImageJ software (Image J, USA National Institutes of
Health, Bethesda, MD, USA).
4.7. Flow Cytometric Analysis of Cell Cycle
Quantitative measurements of the cell cycle phase distribution were performed by flow
cytometry [54]. Cells were suspended in 0.5 mL of hypotonic fluorochrome solution (50 µg/mL
PI, 0.1% sodium citrate, 0.1% Triton X-100). The samples were kept at 4 ◦C in the dark for at least
Int. J. Mol. Sci. 2019, 20, 6122 14 of 18
30 min, dispersed by repeated pipetting before flow cytometry analysis in a FACS Coulter Epics XL
flow cytometer equipped with a single 488 nm argon laser. The percentage of nuclei in the different
phases of the cell cycle (G0-G1, S, and G2-M) was calculated with a DNA cell cycle analysis software
(Cell-Fit, Becton Dickinson). A minimum of 104 cells/sample was analysed for each sample.
4.8. Western Immunoblotting
Enzymatic protein levels were evaluated as previously reported [47] by resolving 35 µg of each
protein sample by SDS-PAGE (12%). The gels were electroblotted onto hydrophobic polyvinylidene
difluoride membranes (Hybond-P PVDF, GE Healthcare Bio-Science, Uppsala, Sweden). Antibody
staining was performed with a chemiluminescence detection system (ECL Plus Western Blotting
Detection Reagent, GE Healthcare Bio-Science, Uppsala, Sweden) using a 1:500 dilution of the mouse
anti-human TS (TS106) monoclonal primary antibody (Invitrogen S.r.L., Milan, Italy), 1:1000 dilutions
of the mouse anti-human DHFR monoclonal antibody (Tebu-Bio, Milan, Italy), and 1:1000 of mouse
anti-human ß-actin antibody (Sigma-Aldrich S.r.L., Milan, Italy) in conjunction with a 1:3000 dilution of
horseradish peroxidase-conjugated sheep anti-mouse secondary antibody (GE Healthcare Bio-Science,
Uppsala, Sweden). Quantification of signal intensity was performed by densitometry on a GS-800
calibrated densitometer (Bio-Rad) and analysed by using Quantity One software (Bio-Rad, Hercules,
CA, USA).
4.9. TS Catalytic Assay
Pellets from exponentially growing cells were thawed by the addition of ice-cold lysis buffer
(200 mM Tris-HCl pH 7.4, 20 mM 2-mercaptoethanol, 100 mM NaF, and 1% Triton X-100), sonicated
(three times 5 s with intervals of 5 s), and centrifuged at 14,000× g for 15 min at 4 ◦C. The supernatant
was used for TS catalytic assay [43] that was based on the measurements of the amounts of 3H release
from 5-[3H]dUMP during its TS catalysed conversion to dTMP. Briefly, the reaction was started by
adding 5-[3H]dUMP (1 µM final concentration, specific activity 5 mCi/mol) to enzyme suspensions in
assay buffer and 650 µM 5,10-methylenetetrahydrofolate in a final volume of 50 µL. After incubation for
60 min at 37 ◦C and blocking by adding 50 µL of ice-cold 35% trichloroacetic acid, residual 5-[3H]dUMP
was removed by the addition of 250 µL of 10% neutral activated charcoal. The charcoal was removed
by centrifugation at 14,000× g for 15 min at 4 ◦C, and a 150 µL sample of the supernatant was assayed
for tritium radioactivity in the liquid scintillator analyzer Tri-Carb 2100 (Packard Inc., Conroe, TX,
USA).
4.10. Radioligand Assay for Folic Acid
To assess folic acid accumulation, uptake studies were conducted with 30 nM [3H] folic acid (FA)
(specific activity 0.5 Ci/mmol) at 37 ◦C [55] in the presence or absence of the tested compounds. Then,
24 h after seeding, the culture medium was replaced with folate-free RPMI 1640 medium for at least an
additional 24 h to maximize the externalization of folate receptor to cell surface. After washing, 0.1 N
NaOH and 0.1% Triton X-100, and 550 µL of this cell lysate were analysed for radioactivity using a
scintillation counter (Tri-Carb 2100, Packard Inc., Conroe, TX, USA) to relate 3H-FA accumulation to
cellular protein content.
4.11. Statistical Analyses
All values report the mean ± the standard error of the mean (SEM), unless otherwise indicated.
p-values were calculated with two-sided Student’s t-test and ANOVA followed by the Tukey′s multiple
comparison. * p < 0.05; ** p <0.01; *** p < 0.001.
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